ClinicalTrials.gg
RecruitingNCT07635186Updated Jul 29, 2026

A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B

A Phase 2 interventional study of AHB-137 and Placebo in Chronic Hepatitis B, sponsored by Ausper Biopharma Co., Ltd.. Recruiting at 34 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Ausper Biopharma Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic — 6 open to participants now, 8 under way, 1 of them phase 3. Hepatitis B Virus Antisense Oligonucleotide AHB-137 · Hepatitis B, Chronic.

Planned enrollment
2nd of 11
320 · median 86
Started
2026
with 3 others
Phase 2
7 of 11
5 open now
Registered
10th of 11
by date
Lead sponsor
8 of 11
Ausper Biopharma Co., Ltd.

Among the 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic, this one is the 2nd largest by planned enrollment, is one of 4 that started in 2026, is one of 7 in phase 2, and was the 10th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

6 of the 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About Hepatitis B Virus Antisense Oligonucleotide AHB-137

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, placebo-controlled, multicenter phase 2 study to assess the efficacy and safety of AHB-137 injection in treatment-naïve participants with chronic hepatitis B.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

Keywords

  • Chronic Hepatitis B
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Volunteer to participate and sign the form, and are willing to complete the study in accordance with the requirements of the protocol.
  • Aged 18-65 years (including boundary values).
  • between the range of 18-32 kg/m2 (inclusive boundary values).
  • or HBV DNA positive for ≥ 6 months at screening and no antiviral treatment with interferon or nucleoside analogue.
  • HBsAg and HBV DNA values met protocol requirements at screening.
  • \< 3xULN at screening.
  • Use highly effective as required.

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled and stable abnormalities other than a history of chronic infection.
  • Participants with other clinically significant liver diseases, previous/current manifestations of hepatic decompensation, and a history of extrahepatic diseases that may be related to HBV immune status.
  • Any serious infection other than chronic hepatitis B infection requiring intravenous anti-infective therapy within 1 month prior to randomization.
  • virus (HCV) infection or \< 12 months from cure at screening (HCV RNA positive within 12 months), (HIV) positive at screening, and syphilis positive (treponema pallidum antibody positive).
  • Significant fibrosis or cirrhosis, or liver stiffness value (LSM) > 9.0 kPa at screening.
  • Participants with confirmed or suspected liver cancer who have a history of within the past 5 years or are undergoing assessment for a possible malignancy.
  • Laboratory test results do not meet the criteria.
  • Prior/current disease, history of vasculitis, or presence of signs, symptoms, or laboratory tests of underlying vasculitis.
  • Fridericia ' s formula interval (QTcF) ≥ 450 msec for male participants and ≥ 470 msec for female participants at screening.
  • Allergic to AHB-137 ingredients, or history of drug allergy or other allergies.
  • Major trauma or major surgery within 3 months prior to screening, or planned surgery during the trial.
  • Participants are participating in another clinical trial or failing to wash out as required.
  • Current use or use of any medication (e.g. prednisone) within 3 months prior to screening, except for short courses (≤ 2 weeks) or use of topical/inhaled ;Those who have used immunomodulators within 3 months prior to screening;Those who have used cytotoxic drugs within 6 months prior to screening;History of vaccination within 1 month prior to screening or a plan during the trial.
  • Participants that require regular long-term anticoagulants.
  • Abnormal thyroid function.
  • Participants that have received any antisense oligonucleic acid, siRNA, capsid assembly modulator (CAM) antiviral drug used to treat chronic hepatitis B.
  • Any other circumstances or conditions in which, in the opinion of the investigator, the participant is inappropriate for participation in this trial.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
320 participants (estimated)

Study arms

  • Experimental
    AHB-137

    AHB-137 will be administered subcutaneously.

    Drug: AHB-137

  • Placebo comparator
    Placebo

    Placebo will be administered subcutaneously.

    Drug: Placebo

Interventions

  • AHB-137 will be administered subcutaneously.

  • DrugPlacebo

    Placebo will be administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. HBV DNA < lower limit of quantitation (LLOQ), 10 IU/mL, HBsAg < limit of detection (LOD), 0.05 IU/mL with or without hepatitis B virus surface antibody (HBsAb) 24 weeks after discontinuation of all chronic hepatitis B treatment.

    Time frame: Up to 48 weeks.

  2. Highly sensitive HBsAg < 0.005 IU/mL and HBV DNA < LLOQ (10 IU/mL) at the end of treatment.

    Time frame: Up to 48 weeks.

Secondary outcomes

  1. HBV DNA < LLOQ, 10 IU/mL, and HBsAg < 10 IU/mL 24 weeks after discontinuation of all chronic hepatitis B treatment.

    Time frame: Up to 48 weeks.

  2. HBV DNA < LLOQ 24 weeks after discontinuation of all chronic hepatitis B treatment.

    Time frame: Up to 48 weeks.

  3. HBV DNA < LLOQ and HBsAg < 100 IU/mL 24 weeks after discontinuation of all chronic hepatitis B treatment.

    Time frame: Up to 48 weeks.

  4. HBsAg seroconversion rate 24 weeks after discontinuation of all chronic hepatitis B treatment.

    HBsAg seroconversion : serum HBsAg\<LOD, and at the same time or subsequently, HBsAb\>10 IU/L.

    Time frame: Up to 48 weeks.

  5. HBeAg seroconversion rate 24 weeks after discontinuation of all chronic hepatitis B treatment.

    HBeAg seroconversion:HBeAg negative, with simultaneous or subsequent positivity for HBeAb.

    Time frame: Up to 48 weeks.

  6. Proportion of participants who discontinued all chronic hepatitis B treatment at the end of treatment.

    Time frame: Up to 48 weeks.

  7. HBV DNA < LLOQ and HBsAg < LOD rate and HBV DNA < LLOQ and HBsAg < 10 IU/mL rate by visit.

    Time frame: Up to 48 weeks.

  8. HBsAg, HBeAg seroconversion rates by visit.

    HBsAg seroconversion: serum HBsAg\<LOD, and at the same time or subsequently, HBsAb\>10 IU/L. HBeAg seroconversion: HBeAg negative, with simultaneous or subsequent positivity for HBeAb.

    Time frame: Up to 48 weeks.

  9. Test Values of Virological Parameters.

    HBsAb, HBsAg, HBV DNA values and changes from baseline at each visit.

    Time frame: Up to 48 weeks.

  10. Time to first achievement of HBsAg and first HBeAg seroconversion.

    HBsAg seroconversion: serum HBsAg\<LOD, and at the same time or subsequently, HBsAb\>10 IU/L. HBeAg seroconversion: HBeAg negative, with simultaneous or subsequent positivity for HBeAb.

    Time frame: Up to 48 weeks.

  11. Changes of the hepatitis B quality of life (HBQOL) instrument in participants compared with baseline.

    Response options range from 1 to 5 with higher scores indicating more severe impact .

    Time frame: Up to 48 weeks.

  12. Changes of the score of EuroQol Five-Dimension Five-Level Scale (EQ-5D-5L) in participants compared with baseline.

    The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the participant's health state.

    Time frame: Up to 48 weeks.

  13. Proportion of participants with protocol-defined virologic response for HBsAg and HBV DNA.

    Time frame: Up to 48 weeks.

  14. Change from baseline in alanine aminotransferase (ALT) and noninvasive assessment of liver fibrosis at each visit.

    Time frame: Up to 48 weeks.

  15. Time to normalization of ALT without rescue therapy (for participants with abnormal baseline ALT).

    Time frame: Up to 48 weeks.

  16. AHB-137 resistance analysis.

    Method: Sequencing of HBV DNA/RNA.

    Time frame: Up to 48 weeks.

  17. Proportion of participants who are HBeAb positive and HBeAg negative, and the test values of HBsAb, HBsAg and HBV DNA meet certain conditions.

    Time frame: Up to 48 weeks.

  18. Safety: number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAE) and clinically significant examination results.

    Examination including laboratory examination, electrocardiogram (ECG) examination.

    Time frame: Up to 48 weeks.

  19. Proportion of participants with positive anti-drug antibody (ADA) and ADA level at each visit.

    Time frame: Up to 48 weeks.

  20. Plasma drug concentration of AHB-137.

    Time frame: Up to 48 weeks.

07

Study locations

34 of 34 sites recruiting
  • AusperBio Investigational Site
    Beijing, Beijing Municipality, China
    Recruiting
  • AusperBio Investigational Site
    Chongqing, Chongqing Municipality, China
    Recruiting
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality, China
    Recruiting
  • AusperBio Investigational Site
    Xiamen, Fujian, China
    Recruiting
  • AusperBio Investigational Site
    Guangzhou, Guangdong, China
    Recruiting
  • AusperBio Investigational Site
    Guangzhou, Guangdong, China
    Recruiting
  • AusperBio Investigational Site
    Guangzhou, Guangdong, China
    Recruiting
  • AusperBio Investigational Site
    Jiangmen, Guangdong, China
    Recruiting
  • AusperBio Investigational Site
    Meizhou, Guangdong, China
    Recruiting
  • AusperBio Investigational Site
    Qingyuan, Guangdong, China
    Recruiting
  • AusperBio Investigational Site
    Shenzhen, Guangdong, China
    Recruiting
  • AusperBio Investigational Site
    Shenzhen, Guangdong, China
    Recruiting
  • AusperBio Investigational Site
    Liuzhou, Guangxi, China
    Recruiting
  • AusperBio Investigational Site
    Wuhan, Hubei, China
    Recruiting
  • AusperBio Investigational Site
    Wuhan, Hubei, China
    Recruiting
  • AusperBio Investigational Site
    Yichang, Hubei, China
    Recruiting
  • AusperBio Investigational Site
    Changsha, Hunan, China
    Recruiting
  • AusperBio Investigational Site
    Changsha, Hunan, China
    Recruiting
  • AusperBio Investigational Site
    Changsha, Hunan, China
    Recruiting
  • AusperBio Investigational Site
    Nanjing, Jiangsu, China
    Recruiting
  • AusperBio Investigational Site
    Nanchang, Jiangxi, China
    Recruiting
  • AusperBio Investigational Site
    Changchun, Jilin, China
    Recruiting
  • AusperBio Investigational Site
    Shenyang, Liaoning, China
    Recruiting
  • AusperBio Investigational Site
    Shanghai, Shanghai Municipality, China
    Recruiting
  • AusperBio Investigational Site
    Shanghai, Shanghai Municipality, China
    Recruiting
  • AusperBio Investigational Site
    Shanghai, Shanghai Municipality, China
    Recruiting
  • AusperBio Investigational Site
    Xi’an, Shanxi, China
    Recruiting
  • AusperBio Investigational Site
    Xi’an, Shanxi, China
    Recruiting
  • AusperBio Investigational Site
    Chengdu, Sichuan, China
    Recruiting
  • AusperBio Investigational Site
    Chengdu, Sichuan, China
    Recruiting
  • AusperBio Investigational Site
    Chengdu, Sichuan, China
    Recruiting
  • AusperBio Investigational Site
    Kunming, Yunan, China
    Recruiting
  • AusperBio Investigational Site
    Hangzhou, Zhejiang, China
    Recruiting
  • The First Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's planned 12 months is below that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2026
First posted
Jun 9, 2026
StartActual
Jun 5, 2026
Primary completionEst.
Jun 20, 2027
CompletionEst.
Jun 20, 2028
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07635186
Responsible party
Sponsor
First posted
Jun 9, 2026
Start date
Jun 5, 2026
Primary completion
Jun 20, 2027 (estimated)
Completion
Jun 20, 2028 (estimated)
Last update
Jul 29, 2026

Study contacts

Lu
Contact
clinicaltrial@ausperbio.com
0571-86959519
Yunqing Qiu
principal investigator · Zhejiang University
Peng Hu
principal investigator · The Second Affiliated Hospital of Chongqing Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hepatitis B Virus Antisense Oligonucleotide AHB-137

Start the discussion